Onyema Eberechukwu Ogbuagu MD
Assistant Professor, Internal Medicine, Yale University School of Medicine
Join to View Full Profile
20 York StNew Haven, CT 06510
Phone+1 203-688-6959
Are you Dr. Ogbuagu?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Onyema Ogbuagu, MD is an infectious disease specialist in New Haven, Connecticut. He is currently licensed to practice medicine in Connecticut and New York. He is an Assistant Professor at Yale University School of Medicine.
Education & Training
Yale-New Haven Medical CenterFellowship, Infectious Disease, 2010 - 2012
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2006 - 2010
University of Calabar Faculty of MedicineClass of 2003
Certifications & Licensure
CT State Medical License 2011 - 2025
NY State Medical License 2010 - 2011
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Publications & Presentations
PubMed
- Efficacy, safety, and pharmacokinetics of lenacapavir oral bridging when subcutaneous lenacapavir cannot be administered.Onyema E Ogbuagu, Anchalee Avihingsanon, Sorana Segal-Maurer, Hui Wang, Vamshi K Jogiraju
AIDS. 2025-05-01 - 10 citationsTwice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.Colleen F Kelley, Maribel Acevedo-Quiñones, Allison L Agwu, Anchalee Avihingsanon, Paul Benson
The New England Journal of Medicine. 2025-04-03 - Drug interactions in people with HIV treated with antivirals for other viral illnesses.Adaora Okoli, Onyema Ogbuagu
Expert Opinion on Drug Metabolism & Toxicology. 2025-04-01
Authored Content
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in PatientsAugust 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in PatientsAugust 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in PatientsAugust 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in PatientsAugust 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in PatientsAugust 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in PatientsAugust 2020
- Join now to see all
Press Mentions
Lenacapavir plus Broadly Neutralising Antibodies Could Be Twice-Yearly HIV TreatmentMarch 12th, 2025- Questioning if It Is Too Late to Get a COVID Vaccine Earlier Than Thanksgiving? Learn ThisNovember 26th, 2024
- Wondering if It's Too Late to Get a COVID Vaccine Before Thanksgiving? Read ThisNovember 25th, 2024
- Join now to see all
Grant Support
- HIV PrEP Perspectives of Liberian Adolescent Girls and Young Women and their ProvidersUNIV OF NORTH CAROLINA CHAPEL HILL2023–2026
